TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Gene Therapy for Ocular Rare Disease Market to Exhibit Phenomenal Growth During the Forecast Period (2025–2034) Due to Expanding Pipeline and Clinical Trial Activities | DelveInsight

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Delveinsight
Gene Therapy for Ocular Rare Disease Market to Exhibit Phenomenal Growth During the Forecast Period (2025–2034) Due to Expanding Pipeline and Clinical Trial Activities | DelveInsight

The gene therapy market for ocular rare diseases is expanding rapidly, with breakthrough viral vector technologies enabling one-time, disease-modifying treatments for inherited retinal disorders. Multiple emerging therapies are expected to transform treatment options for previously untreatable eye conditions.

Insights
OCGN   neutral

Developing investigational gene therapy OCU400 for inherited retinal diseases with potential future market impact